The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.
User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.
The user shared progress pictures after using topical dutasteride for 4 months, experiencing heavy shedding at month 2, which returned to baseline 1.5 months ago. Previous treatments with topical and oral finasteride and minoxidil were ineffective or caused side effects, and the user is hopeful about the shedding phase indicating potential effectiveness of topical dutasteride.
The user experienced significant hair regrowth using a regimen of minoxidil 5% twice daily, finasteride 1 mg daily, microneedling, ketoconazole 2% twice a week, and occasional castor and coconut oil, along with daily scalp massages. They are optimistic about reversing their Norwood 5/6 hair loss.
The user shared their 4-month progress using a topical solution of 5% minoxidil and 0.1% finasteride, reporting initial shedding that stopped after 2.5 months and noticeable regrowth, especially in the crown area. They use Glenmark Hair4U F from India and have experienced no side effects.
The conversation discusses the use of 12.5mg cyproterone every other day for hair loss. There's a concern about reducing testosterone potentially increasing DHT and negatively affecting hair.
The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.
User tried various hair loss treatments with limited success. RU58841 was effective but caused side effects, now trying Eucapil and continuing Finasteride.
Finasteride is effective for DHT/AR-driven hair loss but not for chromosome 20-driven cases, where treatments like minoxidil, prostaglandin analogs, and low-level laser therapy may be more beneficial. Genetic testing can help determine the underlying cause of hair loss to tailor treatment effectively.
SCUBE3 and Amplifica's progress in hair loss treatment is being discussed, with inquiries about their current status and clinical trials. No specific updates or new information are provided in the conversation.
A user reported noticeable hair regrowth using a 272 diode red light therapy hat over 11 months without Minoxidil or Finasteride. Opinions vary on its effectiveness compared to traditional treatments, with some suggesting combining therapies for better results.
A user reported positive results after four months of using finasteride and topical minoxidil for hair loss, with no side effects. They also use ketoconazole shampoo, dermarolling, and rosemary spray.
A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.
PP405 is expected to be available in 2028, with ongoing discussions about its timeline and potential effectiveness. Current treatments mentioned include sublingual Minoxidil and Vederamicd, with some users experiencing side effects from oral Minoxidil.
The user reports positive results from using 0.5 mg dutasteride daily for four months and 2.5 mg oral minoxidil for three months, with no side effects. They switched from topical minoxidil to this oral combination.
The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.
A user shared their 4-month post-hair transplant progress, noting they use oral minoxidil, oral finasteride, biotin pills, and a hair repair serum. They are pleased with the results and hope for increased hair density.
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.
The user is happy with the progress in hair density after using a regimen of oral Dutasteride, topical Minoxidil, Tretinoin cream, Ketoconazole shampoo, and an LLLT helmet. They reported no side effects and noted that Dutasteride and Tretinoin were particularly effective.
Discussing results, side effects and potential sources of pyrilutamide for hair loss treatment alongside RU58841 and other treatments such as Minoxidil and finasteride.
PP405 (Everychem 3HP) may help with hair regrowth, with mixed user experiences. Users often combine it with minoxidil and finasteride, but there are concerns about its efficacy and side effects.
The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.
A 20 year old male's four month progress in treating his hair loss using finasteride, minoxidil, dermarolling and nizoral shampoo, as well as taking daily supplements such as Vitamin D, Zinc and Fish Oil. Replies were made expressing admiration for the results achieved.
Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.
A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.
The conversation discusses a person's 4-month hair loss treatment regimen using topical minoxidil, finasteride, ketoconazole, a dermastamp, and rosemary and peppermint oils. Progress pictures are shared to show the results.
The conversation is about seeking information on GT20029 from Kintor Pharmaceutical as a potential hair loss cure and inquiring about experiences with CosmeaRNA.
PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.
The safety of combining alfatradiol and fluridil with finasteride as a potential treatment for male pattern baldness, which is approved in the European Union. Other treatments such as minoxidil and RU58841 were also discussed.